Literature DB >> 22289918

The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells.

A Zucchetto1, T Vaisitti, D Benedetti, E Tissino, V Bertagnolo, D Rossi, R Bomben, M Dal Bo, M I Del Principe, A Gorgone, G Pozzato, G Gaidano, G Del Poeta, F Malavasi, S Deaglio, V Gattei.   

Abstract

CD49d and CD38 are independent negative prognostic markers in chronic lymphocytic leukemia (CLL). Their associated expression marks a disease subset with a highly aggressive clinical course. Here, we demonstrate a constitutive physical association between the CD49d/CD29 integrin complex and CD38 in primary CLL cells and B-cell lines by (i) cocapping, (ii) coimmunoprecipitation and (iii) cell adhesion experiments using CD49d-specific substrates (vascular-cell adhesion molecule-1 or CS-1/H89 fibronectin fragments). The role of CD38 in CD49d-mediated cell adhesion was studied in CD49d(+)CD38(+) and CD49d(+)CD38(-) primary CLL cells, and confirmed using CD38 transfectants of the originally CD49d(+)CD38(-) CLL-derived cell line Mec-1. Results indicate that CD49d(+)CD38(+) cells adhered more efficiently onto CD49d-specific substrates than CD49d(+)CD38(-) cells (P < 0.001). Upon adhesion, CD49d(+)CD38(+) cells underwent distinctive changes in cell shape and morphology, with higher levels of phosphorylated Vav-1 than CD49d(+)CD38(-) cells (P = 0.0006) and a more complex distribution of F-actin to the adhesion sites. Lastly, adherent CD49d(+)CD38(+) cells were more resistant to serum-deprivation-induced (P < 0.001) and spontaneous (P = 0.03) apoptosis than the CD49d(+)CD38(-) counterpart. Altogether, our results point to a direct role for CD38 in enhancing CD49d-mediated adhesion processes in CLL, thus providing an explanation for the negative clinical impact exerted by these molecules when coexpressed in neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22289918     DOI: 10.1038/leu.2011.369

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  33 in total

1.  CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34(+) hemopoietic progenitors cells.

Authors:  F M Rossi; A Zucchetto; E Tissino; M Dal Bo; R Bomben; C Caldana; F Pozzo; G Del Poeta; D Rossi; G Gaidano; V Gattei
Journal:  Leukemia       Date:  2013-11-08       Impact factor: 11.528

2.  The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.

Authors:  Alba Matas-Céspedes; Anna Vidal-Crespo; Vanina Rodriguez; Neus Villamor; Julio Delgado; Eva Giné; Heleia Roca-Ho; Pablo Menéndez; Elías Campo; Armando López-Guillermo; Dolors Colomer; Gaël Roué; Adrian Wiestner; Paul W H I Parren; Parul Doshi; Jeroen Lammerts van Bueren; Patricia Pérez-Galán
Journal:  Clin Cancer Res       Date:  2016-09-16       Impact factor: 12.531

3.  Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?

Authors:  D Benedetti; E Tissino; C Caldana; M Dal Bo; R Bomben; D Marconi; S Ganghammer; F Zaja; G Pozzato; F Di Raimondo; T N Hartmann; G Del Poeta; A VanMeter; A Zucchetto; V Espina; L Liotta; V Gattei
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

4.  NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.

Authors:  F Pozzo; T Bittolo; F Arruga; P Bulian; P Macor; E Tissino; B Gizdic; F M Rossi; R Bomben; A Zucchetto; D Benedetti; M Degan; G D'Arena; A Chiarenza; F Zaja; G Pozzato; D Rossi; G Gaidano; G Del Poeta; S Deaglio; V Gattei; M Dal Bo
Journal:  Leukemia       Date:  2015-07-13       Impact factor: 11.528

5.  Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells.

Authors:  Silvia Mele; Stephen Devereux; Andrea G Pepper; Elvira Infante; Anne J Ridley
Journal:  Blood Adv       Date:  2018-07-10

6.  The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting.

Authors:  T Vaisitti; V Audrito; S Serra; R Buonincontri; G Sociali; E Mannino; A Pagnani; A Zucchetto; E Tissino; C Vitale; M Coscia; C Usai; C Pepper; V Gattei; S Bruzzone; S Deaglio
Journal:  Leukemia       Date:  2014-07-03       Impact factor: 11.528

7.  CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.

Authors:  Erika Tissino; Federico Pozzo; Dania Benedetti; Chiara Caldana; Tamara Bittolo; Francesca Maria Rossi; Riccardo Bomben; Paola Nanni; Hillarj Chivilò; Ilaria Cattarossi; Eva Zaina; Kevin Norris; Jerry Polesel; Massimo Gentile; Giovanni Tripepi; Riccardo Moia; Enrico Santinelli; Idanna Innocenti; Jacopo Olivieri; Giovanni D'Arena; Luca Laurenti; Francesco Zaja; Gabriele Pozzato; Annalisa Chiarenza; Francesco Di Raimondo; Davide Rossi; Chris Pepper; Tanja Nicole Hartmann; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei; Antonella Zucchetto
Journal:  Blood       Date:  2020-04-09       Impact factor: 22.113

8.  CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.

Authors:  M Dal Bo; P Bulian; R Bomben; A Zucchetto; F M Rossi; F Pozzo; E Tissino; D Benedetti; T Bittolo; P Nanni; I Cattarossi; E Zaina; H Chivilò; M Degan; F Zaja; G Pozzato; A Chiarenza; F Di Raimondo; M I Del Principe; G Del Poeta; D Rossi; G Gaidano; V Gattei
Journal:  Leukemia       Date:  2016-04-25       Impact factor: 11.528

9.  Vaccine-induced plasmablast responses in rhesus macaques: phenotypic characterization and a source for generating antigen-specific monoclonal antibodies.

Authors:  Eduardo L V Silveira; Sudhir P Kasturi; Yevgeniy Kovalenkov; Ata Ur Rasheed; Patryce Yeiser; Zarpheen S Jinnah; Traci H Legere; Bali Pulendran; Francois Villinger; Jens Wrammert
Journal:  J Immunol Methods       Date:  2014-11-08       Impact factor: 2.303

10.  CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.

Authors:  Pietro Bulian; Tait D Shanafelt; Chris Fegan; Antonella Zucchetto; Lilla Cro; Holger Nückel; Luca Baldini; Antonina V Kurtova; Alessandra Ferrajoli; Jan A Burger; Gianluca Gaidano; Giovanni Del Poeta; Chris Pepper; Davide Rossi; Valter Gattei
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.